- Home
- CANF
as 04-23-2025 4:00pm EST
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
| Founded: | 1994 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.9M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 408.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.22 - $4.69 | Next Earning Date: | 05-06-2025 |
| Revenue: | $674,000 | Revenue Growth: | -9.29% |
| Revenue Growth (this year): | 461.72% | Revenue Growth (next year): | -20.66% |
Latest Can-Fite Biopharma Ltd Sponsored ADR (Israel) News
CANF Breaking Stock News: Dive into CANF Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
GlobeNewswire
10 days ago
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
MT Newswires
10 days ago
Can-Fite BioPharma Projects $685 Million in Future Revenue via Collaborations
GlobeNewswire
10 days ago
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
GlobeNewswire
10 days ago
Can-Fite Reports 2024 Financial Results and Clinical Update
ACCESS Newswire
a month ago
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
MT Newswires
a month ago
Can-Fite BioPharma Begins Late-Stage Study of Prospective Psoriasis Medication
GlobeNewswire
a month ago
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Compare CANF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.